Lexeo Therapeutics (LXEO) EBITDA (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of EBITDA data on file, last reported at -$22.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 33.94% year-over-year to -$22.3 million; the trailing twelve-month figure through Mar 2026 stood at -$97.8 million (up 15.91% YoY), and the FY2025 full-year result was -$109.3 million, down 3.3% from the prior year.
• EBITDA climbed to -$22.3 million in Q1 2026, from -$23.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$14.0 million in Q2 2023 to a low of -$33.8 million in Q1 2025.
• A 5-year average of -$22.6 million and a median of -$22.3 million in 2026 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 82.86% in 2024 and soared 33.94% in 2026, its largest moves.
• Tracing LXEO's EBITDA over 5 years: stood at -$15.2 million in 2022, then rose by 1.47% to -$15.0 million in 2023, then tumbled by 82.86% to -$27.4 million in 2024, then increased by 15.58% to -$23.1 million in 2025, then climbed by 3.39% to -$22.3 million in 2026.
• Business Quant data shows LXEO's EBITDA at -$22.3 million in Q1 2026, -$23.1 million in Q4 2025, and -$21.6 million in Q3 2025.